These are press releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 26, 2021- Varian's CRA system has been designated a "breakthrough device" by the FDA because of its potential to offer a more effective treatment for select patients with refractory VT.
-
Apr 8, 2021Company will work closely with Google Cloud and build AI tools for radiation oncology organ segmentation using the Google Cloud AI Platform
-
Mar 25, 2021Patented technology provides interventionalists with 3D-controlled bending and navigation capabilities for peripheral vascular, neurovascular and cardiology indications
-
Mar 2, 2021President and COO Chris Toth to Lead Varian as Part of Siemens Healthineers
-
Feb 24, 2021Multi-year agreement covers comprehensive services in support of exceptional patient care
Nov 19, 2020- First patient in the world to participate in a clinical trial of FLASH therapy-
Oct 19, 2020- Five Oral Presentations, Ten Digital Posters Highlight Varian Products and Innovation
-
Oct 12, 2020The FAST-01 (FeAsibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases) study is a significant milestone in the development of FLASH therapy
-
Sep 15, 2020Proton therapy treatment planning software receives 510(k) clearance
-
Sep 14, 2020Kevin O'Reilly Named Senior Vice President and President of Varian Oncology Systems
-
Sep 10, 2020Adaptive therapy provides the ability to personalize patient treatment at the time of treatment based on patient's anatomy and precise position
-
Aug 2, 2020Cancels Upcoming Third Quarter Conference Call in Light of Pending Transaction with Siemens Healthineers
-
Aug 2, 2020Brings Together Highly Complementary Portfolios to Empower Clinicians and Patients in the Fight Against Cancer
-
Jun 25, 2020- Twenty-five percent absolute survival benefit at 5 years for patients receiving stereotactic ablative radiotherapy to all metastatic lesions
-
May 21, 2020New features help clients safeguard care teams and cancer patients, proactively communicate, and ensure access to care
-
May 18, 2020First member from Southeast Asia, Proton Therapy Pte., Ltd., joins Varian's FlashForward Consortium
-
May 7, 2020The National University Cancer Institute, Singapore, partners with Varian to extend advanced oncology solutions to cancer patients
-
Mar 10, 2020First treatments completed in Australia and The Netherlands
-
Feb 27, 2020
-
Feb 11, 2020Ethos represents a new chapter in democratized cancer care